<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28958" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sezary Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vakiti</surname>
            <given-names>Anusha</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padala</surname>
            <given-names>Sandeep A.</given-names>
          </name>
          <aff>Augusta UMC/ Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Daulath</given-names>
          </name>
          <aff>Stormont Vail Healthcare</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anusha Vakiti declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Padala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daulath Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28958.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Sezary syndrome and mycosis fungoides are the most common forms of cutaneous T-cell lymphoma. This can be a diagnostic challenge to clinicians as it can mimic benign skin disorders. It is hypothesized that Sezary syndrome can evolve gradually from mycosis fungoides or occur spontaneously. Patients with this condition have skin involvement characterized by erythematous plaques or flat patches, which may be single or multiple. The patients need a skin biopsy to evaluate this condition, an excisional lymph node biopsy, and a peripheral smear. This activity describes the presentation of Sezary syndrome and highlights the role of the interprofessional team in managing this malignancy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of Sezary syndrome.</p></list-item><list-item><p>Determine&#x000a0;the pathophysiology of Sezary syndrome.</p></list-item><list-item><p>Assess&#x000a0;the workup of a patient suspected of having Sezary syndrome.</p></list-item><list-item><p>Communicate the importance of improving care coordination among the interprofessional team members to educate patients on the management of their severe pruritis and prescribe medications to relieve the itch, which will enhance the delivery of care for those with Sezary syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28958&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28958">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28958.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sezary syndrome&#x000a0;and&#x000a0;mycosis fungoides are the most common forms of&#x000a0;cutaneous T-cell lymphoma&#x000a0;(CTCL)&#x000a0;and can mimic benign skin disorders.&#x000a0;This&#x000a0;can&#x000a0;be&#x000a0;a diagnostic challenge to clinicians. Though&#x000a0;mycosis fungoides&#x000a0;is the most common cutaneous lymphoma, it constitutes less than 1% of non-Hodgkin lymphoma cases. Researchers&#x000a0;hypothesize&#x000a0;that&#x000a0;Sezary syndrome&#x000a0;can evolve gradually from&#x000a0;mycosis fungoides&#x000a0;or occur spontaneously. Significant evidence has&#x000a0;been established&#x000a0;that Sezary syndrome and&#x000a0;mycosis fungoides&#x000a0;are closely related and constitute the broad spectrum of cutaneous lymphomas.<xref ref-type="bibr" rid="article-28958.r1">[1]</xref><xref ref-type="bibr" rid="article-28958.r2">[2]</xref><xref ref-type="bibr" rid="article-28958.r3">[3]</xref></p>
        <p>Primary cutaneous lymphomas (PCL) are localized to the skin without extracutaneous involvement at the initial diagnosis and are a subset of non-Hodgkin lymphoma. They can originate from T or B lymphocytes called cutaneous T-cell lymphomas or cutaneous B-cell lymphomas (CBCL), respectively.&#x000a0;Cutaneous T-cell lymphoma&#x000a0;is further categorized into 2 types:</p>
        <list list-type="order">
          <list-item>
            <p>An indolent form that includes&#x000a0;mycosis fungoides, lymphomatoid papulosis, and anaplastic large T-cell primary cutaneous lymphoma</p>
          </list-item>
          <list-item>
            <p>An aggressive form that&#x000a0;includes&#x000a0;Sezary syndrome <xref ref-type="bibr" rid="article-28958.r4">[4]</xref><xref ref-type="bibr" rid="article-28958.r5">[5]</xref><xref ref-type="bibr" rid="article-28958.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28958.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact cause for mycosis fungoides and Sezary syndrome&#x000a0;has not been established.&#x000a0;</p>
      </sec>
      <sec id="article-28958.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Mycosis fungoides&#x000a0;tend to affect the older population. Generally, patients older than 50 years&#x000a0;are predisposed&#x000a0;as well as males compared to females with a ratio of 2:1. The incidence of Sezary syndrome&#x000a0;in the United States is about 0.8 to 0.9 cases per million persons per year. Like mycosis fungoides, it tends to affect the elderly population and males more commonly. The incidence is higher in Whites compared to Blacks. There is no genetic predisposition and thus no increased risk of developing Sezary syndrome&#x000a0;in families of affected patients.<xref ref-type="bibr" rid="article-28958.r7">[7]</xref></p>
      </sec>
      <sec id="article-28958.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of most of the cases of Sezary syndrome&#x000a0;is still unknown. However, a small percentage of cases of Sezary syndrome are associated with human T-lymphotropic viruses type 1 and 2 (HTLV-I/II), which are endemic in southern Japan, the Caribbean islands, and part of the Middle East. The typical immunophenotype of abnormal peripheral T-cell population in Sezary syndrome is CD3+, CD4+, CD7-, CD26-, CD8-. Occasionally, sezary syndrome can occur when the malignant population demonstrates a CD8+ phenotype or even a CD4-CD8 phenotype. Sezary syndrome with CD8+ phenotype may be associated with HTLV-I/II or HIV. The tumor cells originate from memory T-cells or skin-homing CD4+ T-cells expressing cutaneous lymphocyte antigen (CLA) and chemokine receptors CCR4 and CCR7. Patients with Sezary syndrome have suppressed immunity, as the malignant cells produce type-2 T-cell (Th2) cytokines, which suppress Th1 immunity by decreasing the production of interleukin-12. The role of interleukin-12 is to stimulate the production of interferon-gamma and tumor necrosis factor-alpha (TNF-a), thus protecting against tumors.</p>
      </sec>
      <sec id="article-28958.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Generally, there are atypical lymphocytes in a sparse dermal infiltrate along with epidermotropism (movement of the atypical lymphocytes into the epidermis), which is suggestive, but not diagnostic, of mycosis fungoides; epidermotropism may be completely absent in biopsies from patients with Sezary syndrome. The more diagnostic intraepidermal aggregates of atypical cells (ie, Pautrier microabscesses) may or may not be present. Significant edema and a nonspecific infiltrate of inflammatory T-cells may predominate, making diagnosis more difficult.<xref ref-type="bibr" rid="article-28958.r8">[8]</xref>&#x000a0;Clonality of T-cell receptor gene rearrangement in the skin by polymerase chain reaction is consistent with, but not diagnostic of, mycosis fungoides and SS.&#x000a0;</p>
      </sec>
      <sec id="article-28958.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The early lesions of mycosis fungoides&#x000a0;mimic psoriasis, chronic eczema, atopic dermatitis, leprosy, or lichenoid pityriasis. The typical skin involvement is thin erythematous plaques or flat patches. They present as single or multiple lesions in the gluteal region or thighs. The lesions can be pruritic and remain stable for many years, go into remission, or grow slowly.</p>
        <p>Sezary syndrome is an erythrodermic&#x000a0;cutaneous T-cell lymphoma&#x000a0;with&#x000a0;a leukemic component. Erythroderma is an intense, widespread, pruritic, exfoliative rash that represents new lesions or progression of prior patches or plaques.</p>
        <p>It is characterized by erythroderma, lymphadenopathy, Sezary or Lutzner cells, atypical circulating lymphocytes, and cutaneous and systemic dissemination of CD4+ T-cells in the blood and the lymph nodes. Mycosis fungoides&#x000a0;are like a patch or a plaque, whereas&#x000a0;Sezary syndrome&#x000a0;presents as a diffuse skin rash. During the disease, it tends to involve about 80% of the total body surface area.&#x000a0;Sezary syndrome&#x000a0;can be considered a leukemic phase of&#x000a0;cutaneous T-cell lymphoma&#x000a0;without any bone marrow compromise. Involvement of the bone marrow can be seen in advanced disease. The other skin lesions associated with Sezary syndrome&#x000a0;include alopecia, keratoderma, hypertrophied nails, lichenification, and ectropion (outward turning of the lower eyelid). Very rarely, it could also involve the&#x000a0;visceral organs. Pruritus is intense and can be debilitating. Even high doses of antihistamines cannot provide relief. Treatment of underlying cancer with steroids has shown to be effective in controlling pruritus. Due to suppressed immunity, affected people are at higher risk for secondary infections (bacterial and viral) and secondary cancers, including Hodgkin and non-Hodgkin lymphomas.</p>
      </sec>
      <sec id="article-28958.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Any patient presenting with erythroderma should raise the suspicion of Sezary syndrome. Though the skin involvement is diffuse in Sezary syndrome, it is not as dense as in mycosis fungoides. Therefore, a skin biopsy should be performed without any interventions for the lesions, and the site with the greatest induration should be biopsied.<xref ref-type="bibr" rid="article-28958.r9">[9]</xref><xref ref-type="bibr" rid="article-28958.r10">[10]</xref><xref ref-type="bibr" rid="article-28958.r11">[11]</xref></p>
        <p>Excisional lymph node biopsy is preferred, and it can show reactive changes, dermatopathic changes, or features suggestive of lymphoma. Peripheral blood shows atypical circulating lymphocytes with grooved nuclei, called Sezary or Lutzner cells. A rarely smaller variant of&#x000a0;Sezary&#x000a0;cells can be seen in normal people or people with known malignancy.<xref ref-type="bibr" rid="article-28958.r12">[12]</xref><xref ref-type="bibr" rid="article-28958.r13">[13]</xref></p>
        <p>Immunophenotyping confirms that T-cell origin (CD3+ and CD4+) and lack of expression of CD2, CD3, CD5, and CD7 (mature T-cell antigens) are supportive of Sezary syndrome. The diagnosis is made by erythroderma involving greater than 80% body surface area, clonal T-cell receptor rearrangement confirmed by polymerase chain reaction or Southern blot, and absolute Sezary cell count of at least 1000 cells/&#x003bc;L, or&#x000a0;1 of the following 2 criteria:</p>
        <list list-type="order">
          <list-item>
            <p>Increased CD4+ or CD3+ with CD4/CD8 ratio of 10 or more</p>
          </list-item>
          <list-item>
            <p>Increased CD4+ cells with abnormal phenotype&#x000a0;(CD4+CD7- ratio of 40% or more or CD4+CD26- ratio of 30% or more)</p>
          </list-item>
        </list>
        <p>The staging of Sezary syndrome&#x000a0;and mycosis fungoides involves evaluating the skin (T), lymph nodes (N), visceral organ involvement (M), and blood (B). The types of skin lesions and the extent of their involvement determine the "T" stage. Blood involvement depends on the tumor burden of the blood. Patients with Sezary syndrome are considered to have stage IVA1, IVA2, and IVB, depending on the presence of nodal and visceral involvement.</p>
      </sec>
      <sec id="article-28958.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment options&#x000a0;are based on the stage of the disease. Given the leukemic involvement in Sezary syndrome, the treatment is generally systemic. It can be given alone or in combination with skin-based therapy. Stage IVA (no visceral involvement) patients are usually treated with extracorporeal phototherapy combined with biological response modifiers (retinoids and interferons). Other alternatives include low-dose methotrexate and histone deacetylase inhibitors (vorinostat and romidepsin). Various combinations of the above can be used along with skin-directed therapy.</p>
        <list list-type="bullet">
          <list-item>
            <p>Skin-directed therapy includes topical or systemic steroids, topical nitrogen mustard, phototherapy (UVB and PUVA), and total skin electron beam therapy.</p>
          </list-item>
          <list-item>
            <p>Radiation therapy can be used for local control of skin and nodal disease.</p>
          </list-item>
          <list-item>
            <p>Patients with stage IVB (visceral involvement) are usually treated with histone deacetylase inhibitors or&#x000a0;targeted therapy like brentuximab vedotin.</p>
          </list-item>
          <list-item>
            <p>Targeted agents approved for&#x000a0;mycosis fungoides/Sezary syndrome include brentuximab vedotin and mogamulizumab. BV is an anti-CD30 monoclonal antibody conjugated with the tubulin inhibitor monomethylauristatin E approved by the FDA for patients who have received prior therapy. Its approval is based on the ALCANZA trial.<xref ref-type="bibr" rid="article-28958.r14">[14]</xref>&#x000a0;Moga is a defucosylated humanized antibody directed against the chemokine receptor CCR4 overexpressed on malignant T-cells. Its approval is based on MAVORIC trial.<xref ref-type="bibr" rid="article-28958.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>In the relapsed and refractory setting, various single-agent chemotherapies can be used, like doxorubicin, gemcitabine, and purine/pyrimidine analogs. FDA-approved drugs in this setting include intermediate-dose methotrexate and pralatrexate. Other options include pembrolizumab, alemtuzumab, bortezomib, and lenalidomide.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Young patients with high-risk diseases should be offered allogeneic hematopoietic stem cell transplantation at experienced centers.</p>
          </list-item>
        </list>
        <p>Besides these disease-directed treatment options, pruritis is a big concern in patients with Sezary syndrome. Various local or systemic options can be used to control the pruritis.<xref ref-type="bibr" rid="article-28958.r16">[16]</xref></p>
      </sec>
      <sec id="article-28958.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Sezary syndrome should be differentiated from mycosis fungoides, psoriasis, pityriasis rubra pilaris, dermatitis, hypereosinophilic syndrome, and adult&#x000a0;T-cell leukemia. Primary skin disorders like scabies, drug eruption, and graft-versus-host disease are also in the differential.&#x000a0;</p>
      </sec>
      <sec id="article-28958.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Skin classification, stage of disease, elevated LDH, advanced age and comorbidities, race, male sex, peripheral eosinophilia, large cell transformation, and folliculotropic&#x000a0;mycosis fungoides have each been associated with poor prognosis and have been variably compiled into validated prognostic indices, including the CTCL Severity Index, the Cutaneous Lymphoma International Prognostic Index, and the Cutaneous Lymphoma International Consortium Prognostic Index.<xref ref-type="bibr" rid="article-28958.r17">[17]</xref></p>
      </sec>
      <sec id="article-28958.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cutaneous T-cell lymphomas are best managed by an interprofessional team that includes oncology nurses. Clinicians caring for patients with cutaneous T-cell malignancies should not forget that they improve their quality of life. These patients have severe pruritus, which can be disabling. Thus, the patient should be educated on moisturizing the skin and prescribed medications to relieve the itch. During treatment of the malignancy, the patient's quality of life should be a consideration. The outlook for most patients is guarded.</p>
      </sec>
      <sec id="article-28958.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28958&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28958">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/sezary-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28958">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28958/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28958">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28958.s14">
        <title>References</title>
        <ref id="article-28958.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cristofoletti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bresin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caprini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Narducci</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Loss of &#x003b2;-arrestin-2 gene and possible functional consequences on Sezary Syndrome.</article-title>
            <source>Cell Cycle</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>1292</fpage>
            <page-range>1292-1294</page-range>
            <pub-id pub-id-type="pmid">31106661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maitre</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Le-Page</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Comoz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Truquet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Damaj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cornet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Verneuil</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sala&#x000fc;n</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Troussard</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Usefulness of Flow Cytometry for the Detection of Cutaneous Localization in Malignant Hematologic Disorders.</article-title>
            <source>Cytometry B Clin Cytom</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>283</fpage>
            <page-range>283-293</page-range>
            <pub-id pub-id-type="pmid">31050147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molloy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jonak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Woei-A-Jin</surname>
                <given-names>FJSH</given-names>
              </name>
              <name>
                <surname>Guenova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Busschots</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bervoets</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hauben</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Porkert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fassnacht</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Papadavid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beylot-Barry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alberti Violetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Estrach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Akilov</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vakeva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bayne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wachsmuch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wehkamp</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Marschalko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Servitje</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weatherhead</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wobser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanches</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Klemke</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Howles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Evison</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scarisbrick</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Characteristics associated with significantly worse quality of life in mycosis fungoides/S&#x000e9;zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.</article-title>
            <source>Br J Dermatol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>182</volume>
            <issue>3</issue>
            <fpage>770</fpage>
            <page-range>770-779</page-range>
            <pub-id pub-id-type="pmid">31049926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>LDS</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kruglov</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Viller</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Lesokhin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Querfeld</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sawas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Sievers</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Shou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Uger</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akilov</surname>
                <given-names>OE</given-names>
              </name>
            </person-group>
            <article-title>Targeting CD47 in S&#x000e9;zary syndrome with SIRP&#x003b1;Fc.</article-title>
            <source>Blood Adv</source>
            <year>2019</year>
            <month>Apr</month>
            <day>09</day>
            <volume>3</volume>
            <issue>7</issue>
            <fpage>1145</fpage>
            <page-range>1145-1153</page-range>
            <pub-id pub-id-type="pmid">30962222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van-de-Velde</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.</article-title>
            <source>J Cutan Med Surg</source>
            <year>2019</year>
            <season>May/Jun</season>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>319</fpage>
            <page-range>319-327</page-range>
            <pub-id pub-id-type="pmid">30943788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <collab>PDQ Adult Treatment Editorial Board</collab>
            <chapter-title>Mycosis Fungoides (Including S&#x000e9;zary Syndrome) Treatment (PDQ&#x000ae;): Patient Version</chapter-title>
            <source>PDQ Cancer Information Summaries [Internet]</source>
            <publisher-name>National Cancer Institute (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>3</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">26389317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>HLJ</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>EST</given-names>
              </name>
              <name>
                <surname>Tee</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Boey</surname>
                <given-names>JJJ</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>MBY</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and prognostic factors for mycosis fungoides and S&#x000e9;zary syndrome in a multi-ethnic Asian cohort: a 12-year review.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>1513</fpage>
            <page-range>1513-1521</page-range>
            <pub-id pub-id-type="pmid">30801779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vonderheid</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>On the diagnosis of erythrodermic cutaneous T-cell lymphoma.</article-title>
            <source>J Cutan Pathol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>33 Suppl 1</volume>
            <fpage>27</fpage>
            <page-range>27-42</page-range>
            <pub-id pub-id-type="pmid">16412210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damasco</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Geskin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Akilov</surname>
                <given-names>OE</given-names>
              </name>
            </person-group>
            <article-title>Nail Changes in S&#x000e9;zary Syndrome: A Single-Center Study and Review of the Literature.</article-title>
            <source>J Cutan Med Surg</source>
            <year>2019</year>
            <season>Jul/Aug</season>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>380</fpage>
            <page-range>380-387</page-range>
            <pub-id pub-id-type="pmid">30917680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alpdogan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kartan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sokol</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Porcu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Systemic therapy of cutaneous T-cell lymphoma (CTCL).</article-title>
            <source>Chin Clin Oncol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <pub-id pub-id-type="pmid">30818958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wain</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Venning</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Consuegra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fernandez-Pe&#x000f1;as</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Management of cutaneous T-cell lymphomas: Established and emergent therapies.</article-title>
            <source>Australas J Dermatol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>200</fpage>
            <page-range>200-208</page-range>
            <pub-id pub-id-type="pmid">30809800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Stang</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <chapter-title>Lymphoproliferative Disorders</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">30725847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shalabi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bistline</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alpdogan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kartan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Porcu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nikbakht</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and S&#x000e9;zary syndrome (SS).</article-title>
            <source>Chin Clin Oncol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <pub-id pub-id-type="pmid">30691274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chairatchaneeboon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Landsburg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of CD30-Negative Refractory Mycosis Fungoides With Brentuximab Vedotin.</article-title>
            <source>JAMA Dermatol</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>154</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <page-range>109-110</page-range>
            <pub-id pub-id-type="pmid">29167875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Bagot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinter-Brown</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rook</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Porcu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tokura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Sokol</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Ortiz-Romero</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Eradat</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Scarisbrick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tsianakas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elmets</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dalle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Halwani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poligone</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fierro</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Khot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Musiek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shustov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Geskin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Dwyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moriya</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hudgens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grebennik</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Duvic</surname>
                <given-names>M</given-names>
              </name>
              <collab>MAVORIC Investigators</collab>
            </person-group>
            <article-title>Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>1192</fpage>
            <page-range>1192-1204</page-range>
            <pub-id pub-id-type="pmid">30100375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cristofoletti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Narducci</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>S&#x000e9;zary Syndrome, recent biomarkers and new drugs.</article-title>
            <source>Chin Clin Oncol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <pub-id pub-id-type="pmid">30525758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28958.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Villasenor-Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary Management of Mycosis Fungoides/S&#x000e9;zary Syndrome.</article-title>
            <source>Curr Hematol Malig Rep</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-243</page-range>
            <pub-id pub-id-type="pmid">28540671</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
